{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:35:54Z","timestamp":1788878154170,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81274054"],"award-info":[{"award-number":["81274054"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7142109"],"award-info":[{"award-number":["7142109"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00769","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T06:42:32Z","timestamp":1509086552000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity"],"prefix":"10.3389","volume":"8","author":[{"given":"Huan-yu","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-jing","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-mei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-feng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-gao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ctrv.2004.05.002","article-title":"New approaches to prevent intestinal toxicity of irinotecan-based regimens","volume":"30","author":"Alimonti","year":"2004","journal-title":"Cancer Treat. Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1349-7006.1993.tb02031.x","article-title":"Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11","volume":"84","author":"Araki","year":"1993","journal-title":"Jpn. J. Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1023\/A:1023847521767","article-title":"Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats","volume":"20","author":"Arimori","year":"2003","journal-title":"Pharm. Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ejps.2008.12.005","article-title":"Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats","volume":"36","author":"Bansal","year":"2009","journal-title":"Eur. J. Pharm. Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jchromb.2016.02.012","article-title":"Development and validation of an UPLC-MS\/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: application to a pharmacokinetic study of irinotecan in rats","volume":"1016","author":"Basu","year":"2016","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci"},{"key":"B6","unstructured":"Guidance for Industry, Bioanalytical Method Validation2001"},{"key":"B7","doi-asserted-by":"publisher","first-page":"7350251","DOI":"10.1155\/2017\/7350251","article-title":"Preventive effects of a Chinese herbal formula, Shengjiang Xiexin Decoction, on irinotecan-induced delayed-onset diarrhea in rats","volume":"2017","author":"Deng","year":"2017","journal-title":"Evid. Based Complement. Altern. Med"},{"key":"B8","unstructured":"Guideline on Bioanalytical Method Validation2011"},{"key":"B9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3109\/03602532.2015.1029634","article-title":"Potential drug interactions associated with glycyrrhizin and glycyrrhetinic acid","volume":"47","author":"Feng","year":"2015","journal-title":"Drug Metab. Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1021\/np9003036","article-title":"Evaluation of the flavonoid oroxylin A as an inhibitor of P-glycoprotein-mediated cellular efflux","volume":"72","author":"Go","year":"2009","journal-title":"J. Nat. Prod"},{"key":"B11","doi-asserted-by":"publisher","first-page":"43621","DOI":"10.1039\/C7RA03521G","article-title":"Comparative intestinal bacteria-associated pharmacokinetics of 16 components of Shengjiang Xiexin decoction between normal rats and rats with irinotecan hydrochloride (CPT-11)-induced gastrointestinal toxicity in vitro using salting-out sample preparation and LC-MS\/MS","volume":"7","author":"Guan","year":"2017","journal-title":"RSC Adv."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1023\/A:1020358910490","article-title":"Reduced gastrointestinal toxicity following Inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats","volume":"19","author":"Horikawa","year":"","journal-title":"Pharm. Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2133\/dmpk.17.23","article-title":"The Potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites","volume":"17","author":"Horikawa","year":"","journal-title":"Drug Metab. Pharmacokinet"},{"key":"B14","first-page":"1189","article-title":"Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2","volume":"60","author":"Humerickhouse","year":"2000","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.clpt.6100019","article-title":"Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein","volume":"81","author":"Jong","year":"2007","journal-title":"Clin. Pharmacol. Ther"},{"key":"B16","first-page":"1136","article-title":"Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients","volume":"7","author":"Kehrer","year":"2001","journal-title":"Clin. Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1172\/JCI119888","article-title":"In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors","volume":"101","author":"Kojima","year":"1998","journal-title":"J. Clin. Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"11747","DOI":"10.1038\/srep11747","article-title":"Inhibition of P-glycoprotein gene expression and function enhances triptolide-induced hepatotoxicity in mice","volume":"5","author":"Kong","year":"2015","journal-title":"Sci. Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/00498259309059356","article-title":"Inhibition of \u03b2-glucuronidase by natural glucuronides of Kampo, medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate","volume":"23","author":"Narita","year":"1993","journal-title":"Xenobiotica"},{"key":"B20","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1177\/0091270004267159","article-title":"Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38","volume":"44","author":"Paoluzzi","year":"2004","journal-title":"J. Clin. Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3969\/j.issn.1001-1528.2017.03.007","article-title":"Shengjiang Xiexin decoction treats irinotecan-induced delayed diarrhea in colorectal carcinoma mice","volume":"39","author":"Peng","year":"2017","journal-title":"Chin. Tradit. Pat. Med"},{"key":"B22","first-page":"4983","article-title":"Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis","volume":"9","author":"Sanghani","year":"2003","journal-title":"Clin. Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1349-7006.1995.tb02994.x","article-title":"A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38","volume":"86","author":"Sasaki","year":"1995","journal-title":"Jpn. J. Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1021\/bc0155420","article-title":"Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug","volume":"12","author":"Senter","year":"2001","journal-title":"Bioconjug. Chem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.13193\/j.issn.1673-7717.2015.09.019","article-title":"Study on effect of Banxia Xiexin decoction on pharmacokinetics of irinotecan in rat by LC-ESI-MS\/MS","volume":"33","author":"Shi","year":"2015","journal-title":"Chin. Arch. Trad. Chin. Med"},{"key":"B26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","article-title":"Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [14C]CPT-11 in cancer patients","volume":"28","author":"Slatter","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"B27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.tiv.2005.06.045","article-title":"Pharmacogenetics of irinotecan metabolism and transport: an update","volume":"20","author":"Smith","year":"2006","journal-title":"Toxicol. In Vitro"},{"key":"B28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2174\/1389450111314070007","article-title":"Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis","volume":"14","author":"Swami","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"B29","first-page":"3752","article-title":"Involvement of \u03b2-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats","volume":"56","author":"Takasuna","year":"1996","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00280-005-0053-0","article-title":"A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer","volume":"57","author":"Tobin","year":"2006","journal-title":"Cancer Chemother. Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1124\/mol.65.6.1336","article-title":"Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity","volume":"65","author":"Wadkins","year":"2004","journal-title":"Mol. Pharmacol"},{"key":"B32","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0090-9556(24)15189-6","article-title":"Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line Hep G2","volume":"28","author":"Walle","year":"2000","journal-title":"Drug Metab. Dispos"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.761\/CJIM.2015.10-1236","article-title":"Effect of Shengjiang Xiexin decoction on the repair of damaged rat intestinal mucosa after irinotecan chemotherapy","volume":"35","author":"Wang","year":"2015","journal-title":"Chin. J. Integr. Tradit. West. Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.2174\/156802612801319034","article-title":"Strategies and techniques for multi-component drug design from medicinal herbs and traditional Chinese medicine","volume":"12","author":"Wang","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2174\/0929867054020972","article-title":"Novel agents that potentially inhibit irinotecan-induced diarrhea","volume":"12","author":"Yang","year":"2005","journal-title":"Curr. Med. Chem"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1124\/dmd.107.015164","article-title":"Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats","volume":"35","author":"Yokoo","year":"2007","journal-title":"Drug Metab. Dispos"},{"key":"B37","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.2042-7158.2012.01592.x","article-title":"Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats","volume":"65","author":"Yokooji","year":"2013","journal-title":"J. Pharm. Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1208\/s12248-010-9209-x","article-title":"Breast cancer resistance protein (BCRP) and sulfotransferases contribute significantly to the disposition of genistein in mouse intestine","volume":"12","author":"Zhu","year":"2010","journal-title":"AAPS J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00769\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:26:21Z","timestamp":1750965981000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00769\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,27]]},"references-count":38,"alternative-id":["10.3389\/fphar.2017.00769"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00769","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,27]]},"article-number":"769"}}